HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”

@inproceedings{Kohli2016HIVA,
  title={
HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”},
  author={Payal Kohli and Peter A Ganz and Yifei Ma and Rebecca Scherzer and Sophia Hur and Bernard Weigel and Carl Grunfeld and Steven G. Deeks and Scott M. Wasserman and Rob Scott and Priscilla Ying Hsue},
  booktitle={Journal of the American Heart Association},
  year={2016}
}
BACKGROUND Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and improve outcomes in the general population. HIV-infected individuals are at increased risk for cardiovascular events and have high rates of dyslipidemia and hepatitis C virus (HCV) coinfection, making PCSK9 inhibition a potentially attractive therapy. METHODS AND RESULTS We studied 567 participants from a clinic-based cohort to compare PCSK9 levels in patients with HIV… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Similar Papers

Loading similar papers…